Endocrine Abstracts

Background: As per 2014 Endocrine Society guidelines, 131I-MIBG therapy is usually reserved for metastatic or unresectable disease in patients with pheochromocytoma / paraganglioma. In this series, we describe three patients effectively treated with primary 131I-MIBG therapy. The indications were primary neo-adjuvant therapy prior to surgery, or palliative.Case series: Case 1 – 18-year-old male with a 60 mm para-aortic paragang...

131I-metaiodobenzylguanide (MIBG) therapy, initially introduced in the 1980s, has emerged as a first-line to treatment of malignant phaeochromocytomas. Its other notable use has been in treating neuroblastomas occurring in childhood serving as an adjuvant prior to surgery or chemotherapy. An observed known late consequence of MIBG therapy is Primary ovarian failure (POI), characterised by menstrual irregularities over a period of 4 months associated with high Follicular stimul...

There is limited research into the impact of active brown adipose tissue (aBAT) in patients with phaeochromocytomas and paragangliomas (PPGLs). A small body of evidence has shown that patients with PPGL patients can exhibit a high prevalence for aBAT recognized as ranging between 8 - 28% without specific correlation to germline mutations. Furthermore, it has been suggested that aBAT may be linked to increased mortality. Systematic searches of the Medical Literature Analysis an...